Please assess the completion status of the following clinical trial:

Trial Title: APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed malignant disease~  * No head and neck cancer or upper gastrointestinal cancer~* Scheduled to receive a single day of moderately or highly emetogenic chemotherapy regimen (for ≤ 4 courses)~  * Chemotherapy administration ≤ 4 hours~ * Duration of each course ≤ 28 days~ * Causing nausea and vomiting in 30-100% of patients if untreated according to Hesketh algorithm~* Must be able to receive standardized doses of dexamethasone for the prevention of emesis during study treatment~* No greater than mild nausea or any vomiting within 24 hours before beginning study treatment~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known allergy or hypersensitivity to other selective 5-HT3 receptor antagonists or local anesthetics~* QTc interval ≤ 500 ms~* No cardiac abnormality predisposing the patient to arrhythmia~* No psychological problem that, in the opinion of the investigator, is severe enough to preclude study participation~* No recent history (i.e., ≤ 1 year) of alcohol or drug abuse~* No concurrent condition that, in the opinion of the investigator, could affect assessment of study medication or interfere with the nausea/vomiting response (e.g., severe renal or hepatic impairment)~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No radiotherapy 7 days prior to, during, and 5 days after completion of study treatment~* More than 7 days since prior chemotherapy~* More than 7 days since prior and no concurrent prohibited medications (e.g., CYP3A4 inhibitors or other antiemetic medications)~* More than 7 days since prior antinausea medications~* More than 30 days since prior treatment on an investigational trial~* No other concurrent corticosteroids or dexamethasone at a different dose than study treatment~* No concurrent use of APF530, palonosetron hydrochloride, or aprepitant as rescue medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.
- Arm II (Type: EXPERIMENTAL): Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
- Arm III (Type: EXPERIMENTAL): Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).